{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:10:06Z","timestamp":1763554206656,"version":"3.45.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11096-025-02025-8","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:14:09Z","timestamp":1761808449000},"page":"2027-2036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medication safety in patients with hepatic disease: proof of concept of a new approach to screen for patients at risk\u2014a retrospective evaluation utilizing electronic prescribing systems"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-0605","authenticated-orcid":false,"given":"Dorothea","family":"Strobach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Grebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2598-1497","authenticated-orcid":false,"given":"Julian","family":"Steinbrech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2305-2746","authenticated-orcid":false,"given":"Maximilian","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8233-7712","authenticated-orcid":false,"given":"Martin J.","family":"Hug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2025_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2165\/00002018-20052806000005","volume":"28","author":"F Delc\u00f2","year":"2005","unstructured":"Delc\u00f2 F, Tchambaz L, Schlienger R, et al. Dose adjustment in patients with liver disease. Drug Saf. 2005;28:529\u201345. https:\/\/doi.org\/10.2165\/00002018-20052806000005.","journal-title":"Drug Saf"},{"key":"2025_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/17425255.2020.1702022","volume":"16","author":"RA Weersink","year":"2020","unstructured":"Weersink RA, Burger DM, Hayward KL, et al. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2020;16:45\u201357. https:\/\/doi.org\/10.1080\/17425255.2020.1702022.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025_CR3","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/apt.12324","volume":"37","author":"JH Lewis","year":"2013","unstructured":"Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37:1132\u201356.","journal-title":"Aliment Pharmacol Ther"},{"key":"2025_CR4","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00228-013-1502-z","volume":"69","author":"CC Franz","year":"2013","unstructured":"Franz CC, Hildbrand C, Born C, et al. Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. Eur J Clin Pharmacol. 2013;69:1565\u201373.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2025_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11096-019-00948-7","volume":"42","author":"D Strobach","year":"2020","unstructured":"Strobach D, Poppele A, Mannell H, et al. Screening for impaired liver function as a risk factor for drug safety at hospital admission of surgical patients. Int J Clin Pharm. 2020;42(1):124\u201331. https:\/\/doi.org\/10.1007\/s11096-019-00948-7.","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"2025_CR6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/hep4.1334","volume":"3","author":"KL Hayward","year":"2019","unstructured":"Hayward KL, Patel PJ, Valery PC, et al. Medication-related problems in outpatients with decompensated cirrhosis: opportunities for harm prevention. Hepatol Commun. 2019;3(5):620\u201331. https:\/\/doi.org\/10.1002\/hep4.1334.","journal-title":"Hepatol Commun"},{"issue":"4","key":"2025_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40264-018-0744-1","volume":"42","author":"RA Weersink","year":"2019","unstructured":"Weersink RA, Taxis K, Drenth JPH, et al. Prevalence of drug prescriptions and potential safety in patients with cirrhosis: a retrospective real-world study. Drug Saf. 2019;42(4):539\u201346. https:\/\/doi.org\/10.1007\/s40264-018-0744-1.","journal-title":"Drug Saf"},{"key":"2025_CR8","unstructured":"Pharmaceutical Care Network Europe Association. PCNE Classification for Drug Related Problems V 9.1. https:\/\/www.pcne.org\/upload\/files\/417_PCNE_classification_V9-1_final.pdf. Accessed 27-04-2025"},{"issue":"8","key":"2025_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00228-019-02688-z","volume":"75","author":"E Cheema","year":"2019","unstructured":"Cheema E, Al-Aryan A, Al-Hamid A. Medicine use and medicine-related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies. Eur J Clin Pharmacol. 2019;75(8):1047\u201358. https:\/\/doi.org\/10.1007\/s00228-019-02688-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2025_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ejim.2015.05.012","volume":"26","author":"B Guignard","year":"2015","unstructured":"Guignard B, Bonnabry P, Perrier A, et al. Drug-related problems identification in general internal medicine: the impact and role of the clinical pharmacist and pharmacologist. Eur J Intern Med. 2015;26(6):399\u2013406. https:\/\/doi.org\/10.1016\/j.ejim.2015.05.012.","journal-title":"Eur J Intern Med"},{"key":"2025_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/ajhp\/zxaa078","volume":"77","author":"SM McConachie","year":"2020","unstructured":"McConachie SM, Raub JN, Yost R, et al. Evaluation of a multidisciplinary approach to reduce internal medicine readmissions using a readmission prediction index. Am J Health-Syst Pharm. 2020;77:950\u20137. https:\/\/doi.org\/10.1093\/ajhp\/zxaa078.","journal-title":"Am J Health-Syst Pharm"},{"issue":"10","key":"2025_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.mpaic.2020.07.001","volume":"21","author":"R Vaja","year":"2020","unstructured":"Vaja R, Rana M. Drugs and the liver. Anaesthesia and Intensive Care Medicine. 2020;21(10):517\u201323. https:\/\/doi.org\/10.1016\/j.mpaic.2020.07.001.","journal-title":"Anaesthesia and Intensive Care Medicine"},{"key":"2025_CR13","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). [International statistical classification of diseases and related health problems]. 10. Revision, German Modification Stand: 15. September 2023"},{"issue":"12","key":"2025_CR14","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1111\/bcp.15469","volume":"88","author":"W Andrikyan","year":"2022","unstructured":"Andrikyan W, Then MI, Ga\u00dfmann KG, et al. Use of medication data alone to identify diagnoses and related contraindications: application of algorithms to close a common documentation gap. Br J Clin Pharmacol. 2022;88(12):5399\u2013411. https:\/\/doi.org\/10.1111\/bcp.15469.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2025_CR15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/jcpt.13597","volume":"47","author":"K Golla","year":"2022","unstructured":"Golla K, Mannell H, Benesic A, et al. Feasibility of the MELD score as a screening tool for pharmacists to identify patients with impaired hepatic function at hospital admission. J Clin Pharm Ther. 2022;47(5):676\u201384. https:\/\/doi.org\/10.1111\/jcpt.13597.","journal-title":"J Clin Pharm Ther"},{"key":"2025_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216814","author":"K Golla","year":"2023","unstructured":"Golla K, Benesic A, Mannell H, et al. Hepatic impairment as a risk factor for drug safety: suitability and comparison of four liver scores as screening tools. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12216814.","journal-title":"J Clin Med"},{"key":"2025_CR17","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","volume":"398","author":"P Gines","year":"2021","unstructured":"Gines P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet. 2021;398:1359\u201376.","journal-title":"Lancet"},{"key":"2025_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406\u201360.","journal-title":"J Hepatol"},{"key":"2025_CR19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1055\/a-0873-4658","volume":"57","author":"AL Gerbes","year":"2019","unstructured":"Gerbes AL, Labenz J, Appenrodt B, et al. Updated S2k-guideline of the German society of gastroenterology, digestive and metabolic diseases: complications of liver cirrhosis. Z Gastroenterol. 2019;57:611\u201380.","journal-title":"Z Gastroenterol"},{"key":"2025_CR20","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). [Anatomic-therapeutic-chemical classification with daily doses. Official version of the ATC-index with DDD for Germany in the year 2024] Available online: https:\/\/www.bfarm.de\/DE\/Kodiersysteme\/Klassifikationen\/ATC\/_node.html"},{"key":"2025_CR21","unstructured":"Bambha K, Kamath PS. Model for endstage liver disease (MELD). UpToDate. This topic last updated Nov 09 2023"},{"issue":"6","key":"2025_CR22","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1053\/j.gastro.2021.08.050","volume":"161","author":"WR Kim","year":"2021","unstructured":"Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887-1895.e4. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.050.","journal-title":"Gastroenterology"},{"issue":"10","key":"2025_CR23","doi-asserted-by":"publisher","first-page":"117863291769127","DOI":"10.1177\/1178632917691270","volume":"24","author":"N Abbas","year":"2017","unstructured":"Abbas N, Makker J, Abbas H, et al. Perioperative care of patients with liver cirrhosis: a review. Health Serv Insights. 2017;24(10):117863291769127020. https:\/\/doi.org\/10.1177\/1178632917691270.","journal-title":"Health Serv Insights"},{"key":"2025_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/bcp.12182","volume":"77","author":"A Albarmawi","year":"2014","unstructured":"Albarmawi A, Czock D, Gauss A, et al. CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol. 2014;77:160\u20139. https:\/\/doi.org\/10.1111\/bcp.12182.","journal-title":"Br J Clin Pharmacol"},{"key":"2025_CR25","unstructured":"European Medicines Agency (2015) Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with de creased renal function. https:\/\/www.ema.europa.eu\/en\/documents\/ scientific-guideline\/guideline-evaluation-pharmacokinetics medicinal-products-patients-decreased-renal-function_en.pdf. Accessed 14.06.2024"},{"issue":"11","key":"2025_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825\u201330. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00007.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2025_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.pharma.2022.12.002","volume":"81","author":"F Osmani","year":"2023","unstructured":"Osmani F, Arab-Zozani M, Shahali Z, et al. Evaluation of the effectiveness of electronic prescription in reducing medical and medical errors (systematic review study). Ann Pharm Fr. 2023;81(3):433\u201345. https:\/\/doi.org\/10.1016\/j.pharma.2022.12.002.","journal-title":"Ann Pharm Fr"},{"issue":"11","key":"2025_CR28","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1111\/jgs.13057","volume":"62","author":"JF Peterson","year":"2014","unstructured":"Peterson JF, Kripalani S, Danciu I, et al. Electronic surveillance and pharmacist intervention for vulnerable older inpatients on high-risk medication regimens. J Am Geriatr Soc. 2014;62(11):2148\u201352. https:\/\/doi.org\/10.1111\/jgs.13057.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"2025_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12911-019-0748-5","volume":"19","author":"C Quintens","year":"2019","unstructured":"Quintens C, De Rijdt T, Van Nieuwenhuyse T, et al. Development and implementation of \u201cCheck of Medication Appropriateness\u201d (CMA): advanced pharmacotherapy-related clinical rules to support medication surveillance. BMC Med Inform Decis Mak. 2019;19(1):29.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"2025_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11011-025-01533-w","volume":"40","author":"EC Herting","year":"2025","unstructured":"Herting EC, Jensen MD, Jepsen P. Lactulose use among patients with alcohol-related liver cirrhosis as a surrogate marker of hepatic encephalopathy: prevalence and association with mortality - a Danish nationwide cohort study. Metab Brain Dis. 2025;40(1):107. https:\/\/doi.org\/10.1007\/s11011-025-01533-w.","journal-title":"Metab Brain Dis"},{"issue":"2","key":"2025_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/medicina61020221","volume":"61","author":"V Perrone","year":"2025","unstructured":"Perrone V, Usala M, Veronesi C, et al. Drug Utilization of Rifaximin-\u03b1 in Patients with Hepatic Encephalopathy: Evidence from Real Clinical Practice in Italy. Medicina (Kaunas). 2025;61(2):221. https:\/\/doi.org\/10.3390\/medicina61020221.","journal-title":"Medicina (Kaunas)"},{"issue":"25","key":"2025_CR32","doi-asserted-by":"publisher","first-page":"00232","DOI":"10.1016\/j.jhep.2025.04.005","volume":"S0168\u20138278","author":"I Naik","year":"2025","unstructured":"Naik I, Yeo YH, Ng WH, et al. Carvedilol is Associated with Lower Risk of Hepatic Decompensation Compared to Other Non-Selective Beta-Blockers in Cirrhosis. J Hepatol. 2025;S0168\u20138278(25):00232\u20136. https:\/\/doi.org\/10.1016\/j.jhep.2025.04.005.","journal-title":"J Hepatol"},{"key":"2025_CR33","unstructured":"UpToDate LexiDrugs Online. Carvedilol: Drug Information. Accessed: 27-04-2025"},{"key":"2025_CR34","unstructured":"[German Summary of Product Characteristics] Carvedilol Hexal\u00ae Tabletten 01.07.2023"},{"key":"2025_CR35","unstructured":"UpToDate LexiDrugs Online. Rifaximin: Drug Information. Accessed: 27\u201304\u20132025"},{"issue":"3","key":"2025_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","volume":"53","author":"European Association for the Study of the Liver","year":"2010","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397\u2013417. https:\/\/doi.org\/10.1016\/j.jhep.2010.05.004.","journal-title":"J Hepatol"},{"key":"2025_CR37","unstructured":"UpToDate LexiDrugs Online. Spironolactone: Drug Information. Accessed: 27\u201304\u20132025"},{"issue":"1","key":"2025_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145\u201372. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022.","journal-title":"J Hepatol"},{"issue":"1","key":"2025_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.15386\/mpr-2629","volume":"97","author":"SI Stan","year":"2024","unstructured":"Stan SI, Biciu\u015fc\u0103 V, Clenciu D, et al. The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review. Med Pharm Rep. 2024;97(1):12\u201325. https:\/\/doi.org\/10.15386\/mpr-2629.","journal-title":"Med Pharm Rep"},{"issue":"5","key":"2025_CR40","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s10620-017-4492-3","volume":"62","author":"I Doycheva","year":"2017","unstructured":"Doycheva I, Watt KD, Rifai G, et al. Increasing burden of chronic liver disease among adolescents and young adults in the USA: a silent epidemic. Dig Dis Sci. 2017;62(5):1373\u201380. https:\/\/doi.org\/10.1007\/s10620-017-4492-3.","journal-title":"Dig Dis Sci"},{"key":"2025_CR41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41512-019-0056-7","volume":"3","author":"S H\u00e4rm\u00e4l\u00e4","year":"2019","unstructured":"H\u00e4rm\u00e4l\u00e4 S, O\u2019Brien A, Parisinos CA, et al. Development and validation of a prediction model to estimate the risk of liver cirrhosis in primary care patients with abnormal liver blood test results: protocol for an electronic health record study in Clinical Practice Research Datalink. Diagn Progn Res. 2019;3:10. https:\/\/doi.org\/10.1186\/s41512-019-0056-7.","journal-title":"Diagn Progn Res"},{"issue":"Suppl 1","key":"2025_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/liv.13682","volume":"38","author":"P Marcellin","year":"2018","unstructured":"Marcellin P, Kutala BK. Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018;38(Suppl 1):2\u20136. https:\/\/doi.org\/10.1111\/liv.13682.","journal-title":"Liver Int"},{"issue":"11","key":"2025_CR43","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/hep4.1612","volume":"4","author":"KL Hayward","year":"2020","unstructured":"Hayward KL, Weersink RA. Improving medication-related outcomes in chronic liver disease. Hepatol Commun. 2020;4(11):1562\u201377. https:\/\/doi.org\/10.1002\/hep4.1612.","journal-title":"Hepatol Commun"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02025-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02025-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02025-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:08:09Z","timestamp":1763554089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02025-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2025"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02025-8","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Ethics approval was obtained from the ethics committee of the LMU University Munich (23-0741).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}